Genomics of Preclinical Prostate Cancer Models

Preclinical models of prostate cancer are used to conduct tests to understand how prostate cancers evade treatment and to determine if novel therapies or treatment combinations will be effective against aggressive prostate cancers. This thesis uses computational analysis of mutations in genes, as well as changes to the activity of those genes to investigate the genomics of the Melbourne Urological Research Alliance (MURAL) cohort of preclinical models. This cohort includes very high-grade prostate cancers, many with rare and difficult to treat pathologies. This research identifies pathology specific differences between models, as well as possible targets for preclinical testing.